{"gene":"LONP1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2021,"finding":"LONP1 cryo-EM structures reveal that human LONP1 adopts both open and closed spiral staircase orientations dictated by substrate and nucleotide; unlike bacterial Lon, it contains a second spiral staircase within the ATPase domain that engages substrate during translocation. Critically, substrate binding within the central ATPase channel alone is insufficient to induce the activated protease conformation—substrate binding within the protease active site is also required, demonstrating that LONP1 can decouple ATPase and protease activities.","method":"Cryo-electron microscopy structural determination; peptidomimetic active-site inhibitor bortezomib used to trap active conformation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures with functional validation via inhibitor trapping in a single rigorous study, multiple conformational states resolved","pmids":["34050165"],"is_preprint":false},{"year":2021,"finding":"LONP1 works with the mtHSP70 chaperone system (specifically co-chaperone DNAJA3) to promote mitochondrial protein folding. LONP1 is required for DNAJA3 and mtHSP70 solubility; its ATPase activity (but not protease activity) is required for this chaperone function. In vitro, LONP1 shows intrinsic chaperone-like activity and collaborates with mtHSP70 to stabilize a folding intermediate of OXA1L.","method":"siRNA knockdown, in vitro chaperone reconstitution assay, ATPase-dead and protease-dead mutants, mass spectrometry of aggregated proteins","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis (ATPase-dead vs protease-dead) plus cellular knockdown with multiple orthogonal methods in one rigorous study","pmids":["33431889"],"is_preprint":false},{"year":2015,"finding":"LONP1 pathogenic mutations causing CODAS syndrome cluster within the AAA+ domain near the ATP-binding pocket; biochemical assays show substrate-specific defects in ATP-dependent proteolysis, and one Amish variant (p.Arg721Gly) homo-oligomerizes poorly in vitro. Patient lymphoblastoid cells show swollen mitochondria with electron-dense inclusions, aggregated MT-CO2 (mtDNA-encoded COX subunit II), and reduced spare respiratory capacity.","method":"Biochemical proteolysis assays with recombinant mutant proteins; native gel oligomerization assay; electron microscopy of patient lymphoblastoid cell mitochondria; immunoblotting","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro enzymatic assays of purified mutant proteins plus cellular characterization, replicated with multiple alleles across two independent studies (PMID 25574826 and 25808063)","pmids":["25574826"],"is_preprint":false},{"year":2011,"finding":"LONP1 mediates heme-induced proteolysis of mature ALAS-1 (5-aminolevulinic acid synthase) in the mitochondrial matrix. Inhibition of LONP1 with inhibitors or siRNA knockdown blocks heme- and metalloporphyrin-induced degradation of ALAS-1 protein, establishing LONP1 as the protease responsible for this feedback regulatory step in heme biosynthesis.","method":"siRNA knockdown of LONP1; pharmacological inhibition; pulse-chase protein turnover assays in human liver cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — two orthogonal loss-of-function approaches (siRNA + inhibitor) with specific substrate readout, replicated across multiple metalloporphyrins","pmids":["21659532"],"is_preprint":false},{"year":2024,"finding":"Artemisinins directly target LONP1, enhance the LONP1–CYP11A1 protein interaction, and facilitate LONP1-catalyzed degradation of CYP11A1, thereby suppressing ovarian androgen synthesis. Overexpression of LONP1 alone replicates the androgen-lowering effect.","method":"Biochemical binding assays, Co-IP, LONP1 overexpression in rodent PCOS models and human patients, mass spectrometry","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct target engagement demonstrated biochemically, validated in both rodent models and human patients with multiple orthogonal approaches","pmids":["38870290"],"is_preprint":false},{"year":2018,"finding":"LONP1 and the mitochondrial processing peptidase MPPαβ are together required for maturation of a subset of mitochondrial matrix proteins (SSBP1, MTERFD3, FASTKD2, CLPX); these proteins accumulate in unprocessed, insoluble form when LONP1 is absent. Prolonged LONP1 depletion also causes loss of mtDNA and suppression of mitochondrial translation via impaired ribosome biogenesis, activates the integrated stress response (ISR), and stabilizes PINK1.","method":"Catalytically dead LONP1 mutant expression; MPP depletion; quantitative proteomics; siRNA knockdown; immunoblotting","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic-dead mutant trapping of substrates plus MPP epistasis; multiple orthogonal methods identifying substrate set","pmids":["30061372"],"is_preprint":false},{"year":2019,"finding":"Mitochondrial LonP1 is phosphorylated by Akt at Ser173 and Ser181, which enhances its protease activity. Interference with this Akt–LonP1 pathway causes accumulation of misfolded subunits of ETC complex II and complex V, impairs oxidative bioenergetics, increases ROS, suppresses mitochondrial trafficking to the cortical cytoskeleton, and inhibits tumor cell migration and invasion.","method":"In vitro kinase assay, site-directed mutagenesis of phosphorylation sites, co-immunoprecipitation, mitochondrial trafficking imaging, tumor growth assays in vivo","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro phosphorylation assay with mutagenesis validation plus multiple functional readouts in vitro and in vivo","pmids":["31406245"],"is_preprint":false},{"year":2019,"finding":"Purified LonP1-P761L (LONP1 pathogenic variant causing neurodegeneration) fails to degrade phosphorylated PDH E1α subunit in vitro, while wild-type LonP1 degrades it. Overexpressing wild-type LonP1 in patient fibroblasts down-regulates phospho-E1α and rescues PDH activity, demonstrating that LONP1 degrades phospho-E1α to maintain pyruvate dehydrogenase function.","method":"In vitro proteolysis assay with purified recombinant proteins; LonP1 overexpression in patient fibroblasts; PDH activity and lactate/pyruvate ratio measurements","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro reconstitution with purified mutant vs wild-type protein; functionally validated in patient fibroblasts","pmids":["30304514"],"is_preprint":false},{"year":2018,"finding":"LonP1 mutant p.Tyr565His cannot bind or degrade a substrate in vitro, consistent with the predicted role of this residue. Mixing p.Tyr565His with wild-type LonP1 retains partial protease activity, but mixing p.Tyr565His with p.Glu733Lys severely depletes activity, consistent with compound heterozygosity causing classical mitochondrial disease.","method":"In vitro proteolysis assay with purified recombinant single and mixed mutant LonP1 proteins","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro proteolysis with defined single mutants and mixtures; direct mechanistic conclusion about compound heterozygosity","pmids":["29518248"],"is_preprint":false},{"year":2014,"finding":"Oxidative post-translational modifications (decreased reduced cysteine, increased tyrosine nitration and protein carbonylation) of LONP1 attenuate its ATP-dependent proteolytic activity in failing mouse hearts. Mitochondria-targeted antioxidants (mitoTEMPO, mitochondria-targeted human catalase) reversed these oxidative modifications and restored LONP1 proteolytic activity; siRNA repression of LONP1 partially canceled the protective antioxidant effects, confirming LONP1 mediates redox-dependent ETC protein turnover.","method":"FITC-casein proteolytic activity assay; immunoblotting for oxidative modifications; in vivo siRNA knockdown; mitochondria-targeted antioxidant treatment; cardiac function measurement","journal":"Circulation. Heart failure","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (activity assay, modification analysis, genetic knockdown, antioxidant rescue) in vivo and in vitro","pmids":["24740269"],"is_preprint":false},{"year":2022,"finding":"In C. elegans, LONP-1 (the LONP1 ortholog) degrades ATFS-1 in healthy mitochondria, preventing its accumulation. In dysfunctional mitochondria, LONP-1-mediated ATFS-1 degradation is impaired, allowing ATFS-1 to accumulate and bind the replicative polymerase POLG to ∆mtDNA. LONP-1 inhibition in C. elegans and human cybrid cells increased ATFS-1/POLG binding to wild-type mtDNAs, improving heteroplasmy ratios and restoring oxidative phosphorylation.","method":"Genetic loss-of-function (lonp-1 deletion), ChIP for POLG-mtDNA binding, heteroplasmy quantification, LONP-1 inhibitor treatment in C. elegans and human cybrids, respirometry","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis plus ChIP plus pharmacological intervention replicated across two organisms (C. elegans and human cybrids)","pmids":["35165413"],"is_preprint":false},{"year":2022,"finding":"Skeletal muscle-specific ablation of LONP1 in mice causes impaired mitochondrial protein turnover leading to mitochondrial dysfunction, reduced muscle fiber size and strength. Mechanistically, accumulation of mitochondrial-retained protein activates the autophagy-lysosome degradation program. Overexpression of ΔOTC (a known LONP1 substrate) in skeletal muscle recapitulates mitochondrial dysfunction, autophagy activation, muscle loss, and weakness.","method":"Conditional muscle-specific LONP1 knockout mice; ΔOTC overexpression; respirometry; autophagy markers; muscle fiber histology and strength testing","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular phenotype plus substrate overexpression epistasis experiment confirming mechanism","pmids":["35173176"],"is_preprint":false},{"year":2023,"finding":"LONP1 selectively degrades succinate dehydrogenase complex iron sulfur subunit B (SDHB) in mature white adipocytes during thermogenic stimulation. LONP1-mediated SDHB degradation raises intracellular succinate levels, altering histone methylation status on thermogenic genes and enabling white-to-beige adipocyte cell fate programming. Disruption of LONP1-dependent proteolysis impairs cold- or β3 adrenergic agonist-induced beige conversion.","method":"Conditional LONP1 disruption in mature adipocytes; mass spectrometry substrate identification; succinate metabolomics; histone methylation ChIP; cold/β3-agonist treatment in vivo and in vitro","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate identified by proteomics and validated functionally; metabolomics and histone ChIP provide mechanistic link; multiple orthogonal methods in one study","pmids":["37217599"],"is_preprint":false},{"year":2023,"finding":"LONP1 degrades HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) in the mitochondrial matrix; LONP1 downregulation causes aberrant HMGCS2 accumulation that disrupts mitochondrial function and accelerates chronic kidney disease progression.","method":"Tubular-specific Lonp1 overexpression and deletion in CKD mouse models; in vitro proteolysis validation; mass spectrometry substrate identification; renal function and mitochondrial function assays","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain- and loss-of-function in vivo with substrate identification by proteomics and in vitro validation","pmids":["36629048"],"is_preprint":false},{"year":2019,"finding":"LonP1 overexpression in mouse hearts protects against ischemia/reperfusion injury by reducing oxidative protein damage, maintaining mitochondrial redox homeostasis, and downregulating Complex I protein levels and activity. LonP1 haploinsufficiency abrogates ischemic preconditioning-mediated cardioprotection and increases infarct size. In NRVMs, LonP1 knockdown upregulates Complex I subunits and ETC activities, increases superoxide production, and causes mitochondrial inner membrane dysmorphology and hyperpolarization.","method":"Cardiac-specific LonP1 transgenic overexpression mice; LonP1+/− haploinsufficient mice; siRNA knockdown in NRVMs; in vivo I/R injury model; respirometry; ETC activity assays","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — both gain- and loss-of-function genetic models with multiple mechanistic readouts in vivo and in vitro","pmids":["30625302"],"is_preprint":false},{"year":2021,"finding":"LONP1 directly interacts with AIFM1 (apoptosis-inducing factor, mitochondria-associated 1); LONP1 ablation in mouse oocytes causes translocation of AIFM1 from cytoplasm to nucleus, triggering apoptosis and progressive oocyte death. Conditional knockout of Lonp1 in oocytes impairs follicular development and causes infertility.","method":"Conditional oocyte-specific Lonp1 knockout mice; Co-IP/LC-MS; immunofluorescence for AIFM1 localization; follicle counting; fertility assays","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular phenotype; AIFM1 interaction confirmed by Co-IP/MS with localization tracking","pmids":["34974310"],"is_preprint":false},{"year":2022,"finding":"LONP1 is identified as a novel mitochondria-associated membrane (MAM) tethering protein; removal of LonP1 substantially reduces MAM formation and causes mitochondrial fragmentation. Cardiac-specific LonP1 deletion impairs MAM integrity, mitochondrial fusion, and activates ER unfolded protein response (UPRER), causing metabolic reprogramming and pathological heart remodeling.","method":"Conditional cardiac-specific LonP1 knockout mice; MAM fractionation; mitochondrial morphology imaging; ER stress markers; cardiac phenotyping","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with MAM fractionation and multiple phenotypic readouts in single lab","pmids":["37333972"],"is_preprint":false},{"year":2022,"finding":"CDDO and its methyl and imidazole derivatives reversibly inhibit LonP1 by a noncompetitive mechanism, blocking ATP hydrolysis and thus proteolysis (allosteric inhibition). CDDO-anhydride inhibits LonP1 ATPase competitively. Docking of CDDO derivatives in the cryo-EM structure identifies a hydrophobic pocket adjacent to the ATP-binding site. A CODAS-causing pathogenic mutation ablates CDDO inhibition. CDDO fails to inhibit the 26S proteasome ATPase, showing selectivity within the AAA+ family.","method":"In vitro ATPase and protease activity assays; competitive vs. noncompetitive kinetic analysis; cryo-EM structure-based docking; site-directed mutagenesis validation; cell-based inhibition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinetic mechanism determination with mutagenesis and structural docking; specificity validated against 26S proteasome; multiple orthogonal methods","pmids":["35151690"],"is_preprint":false},{"year":2023,"finding":"Sirt3 deacetylates LONP1 at lysine 145 (K145) in the N-terminal domain; deacetylation subsequently facilitates ESCRT0 complex sorting and K63-linked ubiquitination of LONP1, resulting in its degradation. Hyperacetylation-mimetic LONP1-K145Q enhances oxidative phosphorylation and accelerates tumor growth, while deacetylation-mimetic K145R produces a calorie-restriction-like phenotype restraining tumorigenesis.","method":"Mass spectrometry identification of deacetylation site; K145Q/K145R mutagenesis; Sirt3 conditional intestinal knockout mice; Seahorse metabolic analysis; ubiquitination assays","journal":"Journal of translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — MS identification of modification site with mutagenesis validation; in vivo conditional KO; functional metabolic readouts; multiple orthogonal methods","pmids":["36739437"],"is_preprint":false},{"year":2020,"finding":"De novo LONP1 mutation p.R301W (located in the N-terminal domain) causes a mitochondrial encephalopathy phenotype characterized by excessive LONP1 proteolytic activity (degrading known substrates TFAM, PINK1, phospho-PDH E1α, mitoribosome subunits MRPL44/MRPL11) combined with loss of LONP1 chaperone activity. The N-terminal domain is required for hexamer stability and for conformational changes necessary to balance proteolytic and chaperone activities.","method":"Functional studies in patient fibroblasts; immunoblotting for proteolytic substrates; respiratory chain activity assays; hexamer stability assays with N-terminal domain mutations","journal":"Mitochondrion","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular functional studies with multiple substrate readouts in single lab; hexamer stability assay; mechanistic conclusion about N-terminal domain","pmids":["31923470"],"is_preprint":false},{"year":2021,"finding":"NEK5 kinase interacts with LonP1 within mitochondria and may be involved in the LonP1-TFAM signaling module. NEK5 kinase activity is required for maintaining mitochondrial mass, functionality, and mtDNA integrity after oxidative damage.","method":"Co-immunoprecipitation of NEK5 and LonP1; NEK5 kinase-dead mutants; mitochondrial mass and mtDNA integrity assays after oxidative damage","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP interaction confirmed; kinase-dead mutagenesis establishes kinase requirement; mitochondrial phenotype readout; single lab","pmids":["33547867"],"is_preprint":false},{"year":2021,"finding":"LONP1 and ClpP share substrates including SHMT2; depletion of both proteases synergistically increases accumulation of unfolded SHMT2, confirming functional substrate overlap. APEX-mediated proximity proteomics identified the specific substrate sets of LONP1 and ClpP within the mitochondrial matrix, including components of OXPHOS, TCA cycle, amino acid and lipid metabolism.","method":"APEX-mediated proximity biotinylation/proteomics; siRNA depletion of LONP1 and ClpP individually and combined; immunoblotting for SHMT2 folding status; cell growth and death assays","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — APEX proximity proteomics with genetic depletion; shared substrate validated by unfolded protein accumulation; single lab","pmids":["33637676"],"is_preprint":false},{"year":2021,"finding":"Mitochondrial LonP1 protease is implicated in the degradation of unstable Parkinson's disease-associated DJ-1/PARK7 missense mutants (A107P, P158Δ, L166P, E163K, L172Q) that associate with mitochondria. siRNA silencing of LONP1 strongly reduces degradation of these mitochondria-associated DJ-1 mutants.","method":"siRNA knockdown of LONP1; immunofluorescence and biochemical fractionation to assess DJ-1 mutant localization; pulse-chase degradation assays in DJ-1-null MEFs","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with direct substrate degradation readout; fractionation confirms mitochondrial localization; single lab","pmids":["33795807"],"is_preprint":false},{"year":2020,"finding":"LONP1 depletion in mouse oocytes during myoblast differentiation causes mitochondrial depolarization, suppresses the PINK1/Parkin pathway, and reduces Mfn2 and Drp1 levels, blocking mitochondrial remodeling and myoblast differentiation into myotubes. LonP1 promotes myoblast differentiation by regulating PINK1/Parkin-mediated mitochondrial network remodeling.","method":"siRNA knockdown of LonP1 in C2C12 myoblasts; PINK1/Parkin pathway immunoblotting; mitochondrial membrane potential assay; fusion/fission protein levels; differentiation assays","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined cellular differentiation phenotype and pathway marker readouts; single lab","pmids":["32936696"],"is_preprint":false},{"year":2022,"finding":"LONP1 is detected in the nucleus (up to 22% of total cellular LONP1). Nuclear LONP1 interacts with heat shock factor 1 (HSF1) and modulates the heat shock response. Nuclear localization is detectable under all conditions but increases in response to heat shock.","method":"Subcellular fractionation; immunofluorescence; Co-immunoprecipitation of LONP1 with HSF1; quantification of nuclear fraction under heat shock","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — fractionation plus Co-IP with HSF1; nuclear localization confirmed but functional link to HSF1 regulation is Co-IP-level evidence; single lab","pmids":["35760833"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of human LonP1 engaging its native substrate TFAM reveals a bipartite search-and-shred mechanism: the N-terminal domain acts as a selective vestibule to recruit and initially unfold substrate tertiary structure, then polypeptide is threaded through the central channel via a hand-over-hand mechanism driven by aromatic pore-loops. Chemical crosslinking mass spectrometry and site-directed mutagenesis uncovered the region of LonP1 engagement of PolG (the catalytic subunit of the mitochondrial replicative polymerase), which promotes proteolysis and regulation of PolG protein levels; PolG2 clinical variants that disrupt a stable Polγ complex lead to enhanced LonP1-mediated PolG degradation.","method":"Single-particle cryo-EM structure of LonP1–TFAM complex; chemical crosslinking mass spectrometry; site-directed mutagenesis; in vitro proteolysis assay of PolG","journal":"Nucleic acids research / Life (Basel)","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with crosslinking MS and mutagenesis in two independent complementary studies","pmids":["38932681","41900996"],"is_preprint":false},{"year":2025,"finding":"A novel ADP-bound, C3-symmetric intermediate state of LONP1 (LONP1C3) is resolved by cryo-EM. This intermediate is stabilized by interaction with folded substrates and is proposed to have 'fold-sensing' capabilities. Additional symmetric and asymmetric states, including a two-fold symmetric split-hexamer conformation, are associated with the transition from LONP1C3 to the active enzyme (LONP1ENZ), providing mechanistic insight into how substrate selection and engagement regulate unfoldase activation.","method":"Cryo-electron microscopy; biochemical ATPase and protease assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — high-resolution structural work but preprint, single study not yet peer-reviewed","pmids":["40950177"],"is_preprint":true},{"year":2025,"finding":"FBXO11 interacts with LONP1 in the cytosol and catalyzes K63-linked ubiquitination of LONP1 to promote its entry into mitochondria. FBXO11 or LONP1 depletion reduces mitochondrial respiration through impaired LONP1 chaperone activity for assembling ETC Complex IV. This reduced mitochondrial respiration imparts myeloid-biased stem cell properties in CD34+ HSPCs.","method":"Co-IP of FBXO11 and LONP1; ubiquitination assay specifying K63-linkage; shRNA depletion; respirometry; Complex IV assembly assay; human xenograft model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus K63-ubiquitination assay plus functional mitochondrial and cellular rescue experiments across in vitro and in vivo xenograft models","pmids":["41289019"],"is_preprint":false},{"year":2025,"finding":"LONP1 degrades DHODH (dihydroorotate dehydrogenase) in hepatocytes in an ATP-dependent manner, thereby lowering orotic acid levels and suppressing ATF3-mediated activation of hepatic stellate cells. Hepatocyte-specific LONP1 deficiency causes DHODH accumulation, elevated orotic acid, and aggravated MASH-induced liver fibrosis; LONP1 overexpression or DHODH inhibition reverses this.","method":"Hepatocyte-specific Lonp1 knockout mice; LONP1 overexpression; transcriptomics/proteomics/metabolomics; in vitro ATP-dependent proteolysis of DHODH; liver biopsy correlation in human MASH patients","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro ATP-dependent proteolysis assay; conditional KO and overexpression in vivo; metabolomics substrate validation; human patient correlation","pmids":["40784490"],"is_preprint":false},{"year":2025,"finding":"LONP1 degrades MPC1 (mitochondrial pyruvate carrier 1) directly; LONP1-mediated MPC1 degradation promotes glycolytic reprogramming and proliferation/migration of pulmonary artery smooth muscle cells in pulmonary hypertension. Rescue experiments confirm MPC1 knockdown abrogates suppressive effects of LONP1 knockdown on glycolysis and proliferation.","method":"LONP1 knockdown and overexpression in PASMCs; MPC1 knockdown and overexpression rescue experiments; in vivo LONP1 knockdown in rat PH models; glycolysis and proliferation assays","journal":"Clinical science (London, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate-rescue epistasis experiment confirms mechanism; in vivo validation; single lab, direct proteolysis not reconstituted in vitro","pmids":["40332105"],"is_preprint":false},{"year":2022,"finding":"Cardiac-specific deletion of Lonp1 in mouse embryos causes severely impaired heart development and embryonic lethality, with mitochondrial swelling, cristae loss, and abnormal protein aggregates. Mechanistically, loss of LONP1 triggers the p-eIF2α–ATF4 pathway; nuclear ATF4 negatively regulates Tfam and promotes Glut1, disrupting the metabolic shift from glycolysis to oxidative phosphorylation required for heart development.","method":"Cardiac-specific conditional Lonp1 knockout mice (embryonic); electron microscopy; ATF4 nuclear translocation assay; Tfam and Glut1 gene expression analysis; metabolic function assays","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined embryonic lethal phenotype; downstream pathway mechanism (ATF4-Tfam-Glut1) established by gene expression and nuclear translocation","pmids":["35237793"],"is_preprint":false},{"year":2025,"finding":"LONP1 promotes β-cell survival and prevents hyperglycemia by facilitating mitochondrial protein folding via its chaperone activity in cooperation with mtHSP70. LONP1 deletion causes mitochondrial protein misfolding, reduced respiratory function, β-cell apoptosis, and hyperglycemia. LONP1 gain-of-function restores human β-cell survival after glucolipotoxicity via a protease-independent mechanism requiring LONP1–mtHSP70 chaperone activity.","method":"Conditional LONP1 knockout mice; LONP1 overexpression in human islets; quantitative proteomics of protein aggregates; respirometry; β-cell apoptosis assays; protease-dead vs. chaperone mutants","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO and gain-of-function with protease-dead vs. chaperone mutant distinction; quantitative proteomics; human islet validation; multiple orthogonal approaches","pmids":["40691304"],"is_preprint":false},{"year":2024,"finding":"LONP1 degrades ACO2 (aconitase 2) to promote hepatocellular carcinoma cell proliferation, migration, and reduced susceptibility to ferroptosis and cuproptosis. LONP1 overexpression leads to decreased mitochondrial membrane potential (mitochondrial dysfunction) and reduced ACO2 protein, inhibiting ferroptosis.","method":"LONP1 overexpression and knockdown in HCC cell lines; subcutaneous tumor xenografts; histological co-staining of LONP1 and ACO2; mitochondrial membrane potential assay; ferroptosis/cuproptosis assays","journal":"Frontiers in bioscience (Landmark edition)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — substrate relationship between LONP1 and ACO2 inferred from co-staining and OE/KD without direct in vitro proteolysis reconstitution; single lab","pmids":["40917061"],"is_preprint":false},{"year":2026,"finding":"LONP-1 (C. elegans LONP1 ortholog) deficiency causes dysregulation of mitochondrial DNA replication, mitochondrial RNA transcription, and protein synthesis. Suppressor mutations in genes encoding mitochondrial ribosome proteins (MRPS-38, MRPS-15) restore mitochondrial function and oxidative phosphorylation in lonp-1 mutants, suggesting LONP-1 regulates mitochondrial protein synthesis and that slowing translation corrects OXPHOS complex assembly defects.","method":"Forward genetic suppressor screen in C. elegans; lonp-1 deletion mutants; mitoribosome gene mutagenesis; respirometry; mtDNA replication and transcription assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (suppressor screen) with defined functional rescue; preprint status reduces confidence","pmids":["41648325"],"is_preprint":true}],"current_model":"LONP1 is an ATP-dependent AAA+ serine protease of the mitochondrial matrix that functions as both a selective protease—degrading oxidized, misfolded, and regulated substrates (including ALAS-1, CYP11A1, TFAM, phospho-PDH E1α, SDHB, HMGCS2, DHODH, MPC1, ACO2, DJ-1 mutants, and PolG)—and an ATP-dependent molecular chaperone that collaborates with the mtHSP70/DNAJA3 system to facilitate protein folding; its proteolytic activity is regulated by Akt-mediated phosphorylation (at Ser173/181), Sirt3-mediated deacetylation (at K145) coupled to K63-ubiquitination and degradation, FBXO11-mediated K63-ubiquitination required for mitochondrial import, and reversible oxidative post-translational modifications; structurally, LONP1 adopts open/closed spiral staircase hexameric conformations gated by both ATPase- and protease-domain substrate engagement, with a C3-symmetric intermediate proposed to sense folded substrates before activating the unfoldase; beyond the matrix it is also found at mitochondria-ER contact sites (MAMs) and in the nucleus where it interacts with HSF1 to modulate the heat shock response."},"narrative":{"mechanistic_narrative":"LONP1 is an ATP-dependent AAA+ serine protease of the mitochondrial matrix that governs mitochondrial proteostasis by selectively degrading regulatory, misfolded, and oxidatively damaged proteins while doubling as an ATP-dependent chaperone [PMID:33431889, PMID:30061372, PMID:38932681, PMID:41900996]. Its enzyme cycle is built on a bipartite \"search-and-shred\" architecture: the N-terminal domain acts as a selective vestibule that recruits and initially unfolds substrate, after which polypeptide is threaded through a central channel by aromatic pore-loops in a hand-over-hand mechanism, with a second ATPase-domain spiral staircase engaging substrate during translocation [PMID:34050165, PMID:38932681, PMID:41900996]. Critically, ATPase and protease activities are decoupled—substrate occupancy of both the central channel and the protease active site is required to license the activated conformation—and an ADP-bound C3-symmetric intermediate is positioned to sense folded substrate before unfoldase activation [PMID:34050165, PMID:40950177]. Through this proteolysis LONP1 sets the levels of a broad regulated substrate set spanning heme synthesis (ALAS-1), steroidogenesis (CYP11A1), mtDNA maintenance and transcription (TFAM, PolG), central carbon and one-carbon metabolism (phospho-PDH E1α, SDHB, ACO2, MPC1, SHMT2), ketogenesis and pyrimidine metabolism (HMGCS2, DHODH), and disease-associated misfolded proteins (DJ-1 mutants) [PMID:21659532, PMID:38870290, PMID:30304514, PMID:37217599, PMID:36629048, PMID:33637676, PMID:38932681, PMID:41900996, PMID:40784490, PMID:40332105]. Independently of proteolysis, its ATPase-driven chaperone activity cooperates with the mtHSP70/DNAJA3 system to fold matrix proteins and assemble respiratory complexes [PMID:33431889, PMID:40691304]. LONP1 activity is tuned by Akt phosphorylation at Ser173/181, reversible oxidative modifications, Sirt3 deacetylation at K145, and FBXO11-mediated K63-ubiquitination that drives its mitochondrial import [PMID:31406245, PMID:24740269, PMID:36739437, PMID:41289019]. Loss-of-function and gain-of-function studies link LONP1 to muscle, cardiac, β-cell, hepatic, and oocyte homeostasis, and to integrated stress and unfolded-protein responses [PMID:35173176, PMID:30625302, PMID:34974310, PMID:35237793, PMID:40691304]. Pathogenic LONP1 mutations clustering in the AAA+ and N-terminal domains cause CODAS syndrome and mitochondrial encephalopathy/neurodegeneration through substrate-specific proteolytic defects and imbalance of protease versus chaperone function [PMID:25574826, PMID:30304514, PMID:29518248, PMID:31923470]. Beyond the matrix, LONP1 is detected at mitochondria-ER contact sites as a MAM tethering factor and in the nucleus, where it interacts with HSF1 [PMID:37333972, PMID:35760833].","teleology":[{"year":2011,"claim":"Established that LONP1 is not merely a bulk quality-control protease but a regulated effector of a metabolic pathway, by identifying its role in feedback control of heme biosynthesis.","evidence":"siRNA and pharmacological inhibition with pulse-chase turnover of ALAS-1 in human liver cells","pmids":["21659532"],"confidence":"High","gaps":["Direct in vitro proteolysis of ALAS-1 not reconstituted","Mechanism of heme-induced substrate recognition unresolved"]},{"year":2014,"claim":"Showed that LONP1 proteolytic activity is itself redox-regulated, linking oxidative damage to its own functional decline in disease.","evidence":"FITC-casein activity assays, oxidative modification immunoblotting, in vivo siRNA, and mitochondria-targeted antioxidant rescue in failing mouse hearts","pmids":["24740269"],"confidence":"High","gaps":["Specific oxidized residues controlling activity not mapped","Which ETC substrates accumulate not fully defined"]},{"year":2015,"claim":"Connected LONP1 to human Mendelian disease, defining CODAS syndrome and demonstrating that AAA+-domain mutations cause substrate-specific proteolytic and oligomerization defects.","evidence":"Recombinant mutant proteolysis assays, native-gel oligomerization, and electron microscopy of patient lymphoblastoid mitochondria","pmids":["25574826"],"confidence":"High","gaps":["Tissue specificity of clinical phenotype unexplained","Full substrate spectrum disrupted by mutations unknown"]},{"year":2018,"claim":"Defined a broad LONP1-dependent maturation and turnover network and showed its depletion triggers integrated stress, PINK1 stabilization, and loss of mtDNA/translation, framing LONP1 as central to matrix proteostasis.","evidence":"Catalytic-dead mutant substrate trapping, MPP epistasis, quantitative proteomics, and siRNA","pmids":["30061372"],"confidence":"High","gaps":["Direct versus indirect substrate processing not always distinguished","Mechanism linking depletion to ribosome biogenesis loss unclear"]},{"year":2018,"claim":"Provided biochemical mechanism for compound heterozygous mitochondrial disease by showing differential proteolytic complementation between mutant LonP1 subunits within hexamers.","evidence":"In vitro proteolysis of purified single and mixed mutant LonP1 proteins","pmids":["29518248"],"confidence":"High","gaps":["Hexamer subunit stoichiometry in patients not measured","Cellular consequences not directly assayed"]},{"year":2019,"claim":"Identified post-translational control of LONP1 by Akt phosphorylation and a specific substrate (phospho-PDH E1α), linking LONP1 activity to bioenergetics, redox, and tumor cell motility.","evidence":"In vitro kinase assays with phospho-site mutagenesis, patient-fibroblast rescue, and tumor and trafficking readouts","pmids":["31406245","30304514"],"confidence":"High","gaps":["How phosphorylation alters hexamer conformation not structurally resolved","Phosphatase reversing the modification unknown"]},{"year":2019,"claim":"Demonstrated dose-dependent cardioprotective and ETC-regulatory roles of LONP1 in ischemia/reperfusion using both gain- and loss-of-function models.","evidence":"Cardiac transgenic overexpression and haploinsufficient mice, NRVM knockdown, in vivo I/R, and respirometry","pmids":["30625302"],"confidence":"High","gaps":["Direct substrates mediating Complex I downregulation not all identified","Relationship to preconditioning signaling incomplete"]},{"year":2020,"claim":"Linked LONP1 to differentiation and to a gain-of-function neurodegeneration mechanism, showing that imbalance toward excess proteolysis at the expense of chaperone function is itself pathogenic.","evidence":"Patient-fibroblast substrate immunoblotting and hexamer stability assays for p.R301W; C2C12 siRNA and PINK1/Parkin pathway analysis","pmids":["31923470","32936696"],"confidence":"Medium","gaps":["N-terminal domain conformational control inferred indirectly","Single-lab functional characterization without structural confirmation"]},{"year":2021,"claim":"Resolved the structural basis of LONP1 catalysis, showing dual spiral staircases and the requirement of both ATPase-channel and protease-site substrate engagement to activate proteolysis, explaining ATPase/protease decoupling.","evidence":"Cryo-EM in multiple conformational states with bortezomib active-site trapping","pmids":["34050165"],"confidence":"High","gaps":["Native folded-substrate engagement not captured in this study","How specific substrates select between states unresolved"]},{"year":2021,"claim":"Separated LONP1 chaperone function from its protease activity, showing ATPase-dependent collaboration with mtHSP70/DNAJA3 to fold matrix proteins.","evidence":"siRNA, in vitro chaperone reconstitution with OXA1L, and ATPase-dead versus protease-dead mutants","pmids":["33431889"],"confidence":"High","gaps":["Structural basis of chaperone handoff to mtHSP70 unknown","Full chaperone client set undefined"]},{"year":2021,"claim":"Expanded the substrate landscape and partner network, defining functional overlap with ClpP (shared substrate SHMT2), the NEK5-LonP1-TFAM module, AIFM1 control of oocyte survival, and degradation of mitochondria-associated DJ-1 mutants.","evidence":"APEX proximity proteomics with dual protease depletion; Co-IP of NEK5 and AIFM1; oocyte conditional KO; siRNA pulse-chase of DJ-1 mutants","pmids":["33637676","33547867","34974310","33795807"],"confidence":"Medium","gaps":["NEK5 phosphorylation of LonP1 not directly shown","DJ-1 mutant degradation not reconstituted in vitro","Several interactions rest on single Co-IP"]},{"year":2022,"claim":"Extended LONP1 beyond matrix proteolysis to ATFS-1/UPRmt-coupled mtDNA quality control, MAM tethering, and ER-stress/development signaling, and tied substrate accumulation to autophagy and muscle wasting.","evidence":"C. elegans/cybrid genetics with ChIP and heteroplasmy; muscle and cardiac conditional KO with ΔOTC substrate epistasis; embryonic cardiac KO with ATF4-Tfam-Glut1 analysis; MAM fractionation","pmids":["35165413","35173176","35237793","37333972"],"confidence":"High","gaps":["MAM tethering mechanism is single-lab/Medium evidence","How matrix protease activity produces ER/MAM phenotypes mechanistically unclear"]},{"year":2022,"claim":"Defined selective small-molecule pharmacology of LonP1 and detected a nuclear LONP1 pool interacting with HSF1, broadening its regulatory reach.","evidence":"In vitro ATPase/protease kinetics and cryo-EM docking of CDDO derivatives with mutagenesis; subcellular fractionation and Co-IP of nuclear LONP1 with HSF1","pmids":["35151690","35760833"],"confidence":"Medium","gaps":["Functional consequence of LONP1-HSF1 interaction rests on Co-IP","Nuclear LONP1 import/processing route unknown"]},{"year":2023,"claim":"Identified additional regulated substrates that couple LONP1 to metabolic and epigenetic programming (SDHB-succinate-histone methylation in beiging; HMGCS2 in kidney) and a deacetylation/ubiquitination switch controlling LONP1 stability.","evidence":"Adipocyte and renal conditional KO/overexpression with proteomics and metabolomics; MS site mapping of K145, Sirt3 KO, and K63-ubiquitination assays","pmids":["37217599","36629048","36739437"],"confidence":"High","gaps":["ESCRT0-mediated LONP1 turnover route incompletely defined","Tissue specificity of substrate selection unexplained"]},{"year":2024,"claim":"Captured LonP1 engaging a native substrate (TFAM) to define the search-and-shred mechanism and mapped PolG engagement, linking LONP1 to mitochondrial polymerase regulation and drug-induced (artemisinin) substrate degradation.","evidence":"Cryo-EM of LonP1-TFAM, crosslinking MS and mutagenesis on PolG, in vitro proteolysis; biochemical binding and Co-IP for artemisinin-enhanced CYP11A1 degradation in PCOS models","pmids":["38932681","41900996","38870290"],"confidence":"High","gaps":["Generalizability of N-domain vestibule selectivity to all substrates untested","Artemisinin binding site on LONP1 not structurally resolved"]},{"year":2025,"claim":"Resolved a fold-sensing C3-symmetric intermediate and defined import-coupled and metabolic roles, including FBXO11-driven mitochondrial import, chaperone-dependent β-cell survival, and proteolytic control of DHODH, MPC1, and ACO2 across disease contexts.","evidence":"Cryo-EM intermediate states (preprint); Co-IP and K63-ubiquitination with respirometry (FBXO11); conditional KO/overexpression with protease-dead vs chaperone mutants and human islet/MASH/PH/HCC models","pmids":["40950177","41289019","40691304","40784490","40332105","40917061"],"confidence":"High","gaps":["Intermediate-state model is preprint and awaits peer review","ACO2 substrate relationship inferred without in vitro reconstitution","How FBXO11 K63-ubiquitination mechanistically promotes import unclear"]},{"year":null,"claim":"How LONP1 integrates its multiple post-translational regulatory inputs (phosphorylation, oxidation, acetylation, ubiquitination) with conformational state to select among its diverse substrates, and how nuclear/MAM pools are established and function, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state to substrate choice","Nuclear LONP1 function beyond HSF1 Co-IP undefined","Structural basis of extramitochondrial localization unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,5,7,13,25,28]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,7,13,28]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,1,17,28]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[1,31]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[10,25]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,5,25]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,5,25,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,7,12,13,28,29]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[5,9,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,7,8,19]}],"complexes":[],"partners":["DNAJA3","HSPA9","CYP11A1","AIFM1","HSF1","NEK5","FBXO11","POLG"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P36776","full_name":"Lon protease homolog, mitochondrial","aliases":["LONHs","Lon protease-like protein","LONP","Mitochondrial ATP-dependent protease Lon","Serine protease 15"],"length_aa":959,"mass_kda":106.5,"function":"ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix (PubMed:12198491, PubMed:15870080, PubMed:17579211, PubMed:37327776, PubMed:8248235). Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein, DELE1, helicase Twinkle (TWNK) and the large ribosomal subunit protein MRPL32/bL32m (PubMed:17579211, PubMed:28377575, PubMed:37327776). MRPL32/bL32m is protected from degradation by LONP1 when it is bound to a nucleic acid (RNA), but TWNK is not (PubMed:17579211, PubMed:28377575). May also have a chaperone function in the assembly of inner membrane protein complexes (By similarity). Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome (PubMed:17420247). Binds to mitochondrial promoters and RNA in a single-stranded, site-specific, and strand-specific manner (PubMed:17420247). May regulate mitochondrial DNA replication and/or gene expression using site-specific, single-stranded DNA binding to target the degradation of regulatory proteins binding to adjacent sites in mitochondrial promoters (PubMed:14739292, PubMed:17420247)","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/P36776/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/LONP1","classification":"Common Essential","n_dependent_lines":1178,"n_total_lines":1208,"dependency_fraction":0.9751655629139073},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ANKRD17","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"ESD","stoichiometry":0.2},{"gene":"HEATR3","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HNRNPH1","stoichiometry":0.2},{"gene":"RBM14","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/LONP1","total_profiled":1310},"omim":[{"mim_id":"617774","title":"LON PEPTIDASE 2, PEROXISOMAL; LONP2","url":"https://www.omim.org/entry/617774"},{"mim_id":"617469","title":"AFG1-LIKE ATPase; AFG1L","url":"https://www.omim.org/entry/617469"},{"mim_id":"616854","title":"EVEN-PLUS SYNDROME; EVPLS","url":"https://www.omim.org/entry/616854"},{"mim_id":"605490","title":"LON PEPTIDASE 1, MITOCHONDRIAL; LONP1","url":"https://www.omim.org/entry/605490"},{"mim_id":"600373","title":"CODAS SYNDROME","url":"https://www.omim.org/entry/600373"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adrenal gland","ntpm":190.0}],"url":"https://www.proteinatlas.org/search/LONP1"},"hgnc":{"alias_symbol":["LonHS","hLON","PIM1"],"prev_symbol":["PRSS15"]},"alphafold":{"accession":"P36776","domains":[{"cath_id":"2.30.130.40","chopping":"109-221","consensus_level":"medium","plddt":83.6251,"start":109,"end":221},{"cath_id":"1.20.58","chopping":"288-379","consensus_level":"medium","plddt":81.3822,"start":288,"end":379},{"cath_id":"-","chopping":"414-468","consensus_level":"medium","plddt":88.432,"start":414,"end":468},{"cath_id":"3.40.50.300","chopping":"481-658","consensus_level":"medium","plddt":88.2556,"start":481,"end":658},{"cath_id":"1.10.8.60","chopping":"664-747","consensus_level":"medium","plddt":91.1442,"start":664,"end":747},{"cath_id":"3.30.230.10","chopping":"765-959","consensus_level":"high","plddt":85.5157,"start":765,"end":959}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36776","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36776-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36776-F1-predicted_aligned_error_v6.png","plddt_mean":76.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LONP1","jax_strain_url":"https://www.jax.org/strain/search?query=LONP1"},"sequence":{"accession":"P36776","fasta_url":"https://rest.uniprot.org/uniprotkb/P36776.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36776/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36776"}},"corpus_meta":[{"pmid":"25574826","id":"PMC_25574826","title":"CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon protease.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25574826","citation_count":130,"is_preprint":false},{"pmid":"33431889","id":"PMC_33431889","title":"LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33431889","citation_count":110,"is_preprint":false},{"pmid":"21659532","id":"PMC_21659532","title":"Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21659532","citation_count":106,"is_preprint":false},{"pmid":"38870290","id":"PMC_38870290","title":"Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38870290","citation_count":101,"is_preprint":false},{"pmid":"30061372","id":"PMC_30061372","title":"LONP1 Is Required for Maturation of a Subset of Mitochondrial Proteins, and Its Loss Elicits an Integrated Stress Response.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30061372","citation_count":89,"is_preprint":false},{"pmid":"35165413","id":"PMC_35165413","title":"LONP-1 and ATFS-1 sustain deleterious heteroplasmy by promoting mtDNA replication in dysfunctional mitochondria.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35165413","citation_count":80,"is_preprint":false},{"pmid":"30625302","id":"PMC_30625302","title":"Mitochondrial LonP1 protects cardiomyocytes from ischemia/reperfusion injury in vivo.","date":"2019","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30625302","citation_count":78,"is_preprint":false},{"pmid":"35173176","id":"PMC_35173176","title":"Disuse-associated loss of the protease LONP1 in muscle impairs mitochondrial function and causes reduced skeletal muscle mass and strength.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35173176","citation_count":72,"is_preprint":false},{"pmid":"25808063","id":"PMC_25808063","title":"Mutations in LONP1, a mitochondrial matrix protease, cause CODAS syndrome.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25808063","citation_count":68,"is_preprint":false},{"pmid":"32475470","id":"PMC_32475470","title":"The biology of Lonp1: More than a mitochondrial protease.","date":"2020","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32475470","citation_count":63,"is_preprint":false},{"pmid":"34050165","id":"PMC_34050165","title":"Structures of the human LONP1 protease reveal regulatory steps involved in protease activation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34050165","citation_count":62,"is_preprint":false},{"pmid":"24740269","id":"PMC_24740269","title":"Oxidative post-translational modifications develop LONP1 dysfunction in pressure overload heart failure.","date":"2014","source":"Circulation. Heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/24740269","citation_count":61,"is_preprint":false},{"pmid":"36629048","id":"PMC_36629048","title":"LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36629048","citation_count":59,"is_preprint":false},{"pmid":"29518248","id":"PMC_29518248","title":"Defective mitochondrial protease LonP1 can cause classical mitochondrial disease.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29518248","citation_count":57,"is_preprint":false},{"pmid":"33637676","id":"PMC_33637676","title":"LONP1 and ClpP cooperatively regulate mitochondrial proteostasis for cancer cell survival.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33637676","citation_count":56,"is_preprint":false},{"pmid":"30038898","id":"PMC_30038898","title":"LonP1 Differently Modulates Mitochondrial Function and Bioenergetics of Primary Versus Metastatic Colon Cancer Cells.","date":"2018","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30038898","citation_count":51,"is_preprint":false},{"pmid":"31406245","id":"PMC_31406245","title":"Akt phosphorylation of mitochondrial Lonp1 protease enables oxidative metabolism and advanced tumor traits.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31406245","citation_count":50,"is_preprint":false},{"pmid":"34974310","id":"PMC_34974310","title":"The mitochondrial protease LONP1 maintains oocyte development and survival by suppressing nuclear translocation of AIFM1 in mammals.","date":"2021","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/34974310","citation_count":48,"is_preprint":false},{"pmid":"34547244","id":"PMC_34547244","title":"Rare and de novo variants in 827 congenital diaphragmatic hernia probands implicate LONP1 as candidate risk gene.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34547244","citation_count":44,"is_preprint":false},{"pmid":"26852705","id":"PMC_26852705","title":"The peroxisomal Lon protease LonP2 in aging and disease: functions and comparisons with mitochondrial Lon protease LonP1.","date":"2016","source":"Biological reviews of the Cambridge Philosophical Society","url":"https://pubmed.ncbi.nlm.nih.gov/26852705","citation_count":39,"is_preprint":false},{"pmid":"36978846","id":"PMC_36978846","title":"The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases.","date":"2023","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36978846","citation_count":38,"is_preprint":false},{"pmid":"37333972","id":"PMC_37333972","title":"LonP1 Links Mitochondria-ER Interaction to Regulate Heart Function.","date":"2023","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/37333972","citation_count":37,"is_preprint":false},{"pmid":"31822343","id":"PMC_31822343","title":"Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31822343","citation_count":36,"is_preprint":false},{"pmid":"30304514","id":"PMC_30304514","title":"Bi-allelic mutations of LONP1 encoding the mitochondrial LonP1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30304514","citation_count":33,"is_preprint":false},{"pmid":"36064070","id":"PMC_36064070","title":"LONP1 downregulation with ageing contributes to osteoarthritis via mitochondrial dysfunction.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36064070","citation_count":31,"is_preprint":false},{"pmid":"35237793","id":"PMC_35237793","title":"LONP1-mediated mitochondrial quality control safeguards metabolic shifts in heart development.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35237793","citation_count":30,"is_preprint":false},{"pmid":"32720218","id":"PMC_32720218","title":"Chronic hyperglycemia impairs mitochondrial unfolded protein response and precipitates proteotoxicity in experimental diabetic neuropathy: focus on LonP1 mediated mitochondrial regulation.","date":"2020","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/32720218","citation_count":30,"is_preprint":false},{"pmid":"37217599","id":"PMC_37217599","title":"Proteolytic rewiring of mitochondria by LONP1 directs cell identity switching of adipocytes.","date":"2023","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37217599","citation_count":29,"is_preprint":false},{"pmid":"31356822","id":"PMC_31356822","title":"Ameliorative effect of ursolic acid on ochratoxin A-induced renal cytotoxicity mediated by Lonp1/Aco2/Hsp75.","date":"2019","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/31356822","citation_count":27,"is_preprint":false},{"pmid":"31387295","id":"PMC_31387295","title":"CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31387295","citation_count":25,"is_preprint":false},{"pmid":"36739437","id":"PMC_36739437","title":"Sirt3 restricts tumor initiation via promoting LONP1 deacetylation and K63 ubiquitination.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36739437","citation_count":24,"is_preprint":false},{"pmid":"32521756","id":"PMC_32521756","title":"Impaired Mitochondrial Morphology and Functionality in Lonp1wt/- Mice.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32521756","citation_count":24,"is_preprint":false},{"pmid":"33671345","id":"PMC_33671345","title":"The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33671345","citation_count":24,"is_preprint":false},{"pmid":"36587836","id":"PMC_36587836","title":"Lonp1 and Sig-1R contribute to the counteraction of ursolic acid against ochratoxin A-induced mitochondrial apoptosis.","date":"2022","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/36587836","citation_count":23,"is_preprint":false},{"pmid":"31639451","id":"PMC_31639451","title":"LONP1 induction by SRT1720 attenuates mitochondrial dysfunction against high glucose induced neurotoxicity in PC12 cells.","date":"2019","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/31639451","citation_count":23,"is_preprint":false},{"pmid":"35151690","id":"PMC_35151690","title":"Inhibition of mitochondrial LonP1 protease by allosteric blockade of ATP binding and hydrolysis via CDDO and its derivatives.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35151690","citation_count":22,"is_preprint":false},{"pmid":"34461102","id":"PMC_34461102","title":"Proteomic analysis demonstrates the role of the quality control protease LONP1 in mitochondrial protein aggregation.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34461102","citation_count":22,"is_preprint":false},{"pmid":"31923470","id":"PMC_31923470","title":"LONP1 de novo dominant mutation causes mitochondrial encephalopathy with loss of LONP1 chaperone activity and excessive LONP1 proteolytic activity.","date":"2020","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/31923470","citation_count":21,"is_preprint":false},{"pmid":"36190692","id":"PMC_36190692","title":"Transcranial Direct-Current Stimulation Regulates MCT1-PPA-PTEN-LONP1 Signaling to Confer Neuroprotection After Rat Cerebral Ischemia-Reperfusion Injury.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36190692","citation_count":21,"is_preprint":false},{"pmid":"35456042","id":"PMC_35456042","title":"Organismal and Cellular Stress Responses upon Disruption of Mitochondrial Lonp1 Protease.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35456042","citation_count":20,"is_preprint":false},{"pmid":"33668863","id":"PMC_33668863","title":"LONP1 Regulates Mitochondrial Accumulations of HMGB1 and Caspase-3 in CA1 and PV Neurons Following Status Epilepticus.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33668863","citation_count":20,"is_preprint":false},{"pmid":"28148925","id":"PMC_28148925","title":"A novel mutation in the proteolytic domain of LONP1 causes atypical CODAS syndrome.","date":"2017","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28148925","citation_count":20,"is_preprint":false},{"pmid":"33547867","id":"PMC_33547867","title":"NEK5 interacts with LonP1 and its kinase activity is essential for the regulation of mitochondrial functions and mtDNA maintenance.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33547867","citation_count":19,"is_preprint":false},{"pmid":"38156441","id":"PMC_38156441","title":"Powering down the mitochondrial LonP1 protease: a novel strategy for anticancer therapeutics.","date":"2023","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/38156441","citation_count":18,"is_preprint":false},{"pmid":"33821636","id":"PMC_33821636","title":"Structure-Based Design of Selective LONP1 Inhibitors for Probing In Vitro Biology.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33821636","citation_count":18,"is_preprint":false},{"pmid":"30865517","id":"PMC_30865517","title":"Acute increases in O-GlcNAc indirectly impair mitochondrial bioenergetics through dysregulation of LonP1-mediated mitochondrial protein complex turnover.","date":"2019","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30865517","citation_count":18,"is_preprint":false},{"pmid":"32342250","id":"PMC_32342250","title":"Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease.","date":"2020","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/32342250","citation_count":17,"is_preprint":false},{"pmid":"31756517","id":"PMC_31756517","title":"Cell stress management by the mitochondrial LonP1 protease - Insights into mitigating developmental, oncogenic and cardiac stress.","date":"2019","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/31756517","citation_count":16,"is_preprint":false},{"pmid":"35760833","id":"PMC_35760833","title":"Evidence for mitochondrial Lonp1 expression in the nucleus.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35760833","citation_count":15,"is_preprint":false},{"pmid":"38091289","id":"PMC_38091289","title":"Intraneuronal β-amyloid impaired mitochondrial proteostasis through the impact on LONP1.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38091289","citation_count":15,"is_preprint":false},{"pmid":"31091208","id":"PMC_31091208","title":"Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition.","date":"2019","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/31091208","citation_count":15,"is_preprint":false},{"pmid":"31547314","id":"PMC_31547314","title":"Global Proteome of LonP1+/- Mouse Embryonal Fibroblasts Reveals Impact on Respiratory Chain, but No Interdependence between Eral1 and Mitoribosomes.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31547314","citation_count":15,"is_preprint":false},{"pmid":"40691304","id":"PMC_40691304","title":"LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40691304","citation_count":14,"is_preprint":false},{"pmid":"31636596","id":"PMC_31636596","title":"Expanding the Clinical Spectrum of LONP1-Related Mitochondrial Cytopathy.","date":"2019","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31636596","citation_count":13,"is_preprint":false},{"pmid":"33795807","id":"PMC_33795807","title":"Mitochondrial LonP1 protease is implicated in the degradation of unstable Parkinson's disease-associated DJ-1/PARK 7 missense mutants.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33795807","citation_count":13,"is_preprint":false},{"pmid":"32936696","id":"PMC_32936696","title":"LonP1 regulates mitochondrial network remodeling through the PINK1/Parkin pathway during myoblast differentiation.","date":"2020","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32936696","citation_count":11,"is_preprint":false},{"pmid":"38703850","id":"PMC_38703850","title":"m6A-methylated Lonp1 drives mitochondrial proteostasis stress to induce testicular pyroptosis upon environmental cadmium exposure.","date":"2024","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/38703850","citation_count":11,"is_preprint":false},{"pmid":"34154043","id":"PMC_34154043","title":"Expression of LONP1 Is High in Visceral Adipose Tissue in Obesity, and Is Associated with Glucose and Lipid Metabolism.","date":"2021","source":"Endocrinology and metabolism (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/34154043","citation_count":11,"is_preprint":false},{"pmid":"39181129","id":"PMC_39181129","title":"Context-dependent roles of mitochondrial LONP1 in orchestrating the balance between airway progenitor versus progeny cells.","date":"2024","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/39181129","citation_count":10,"is_preprint":false},{"pmid":"37647804","id":"PMC_37647804","title":"Mitochondrial oxidative stress regulates LonP1-TDP-43 pathway and rises mitochondrial damage in carbon tetrachloride-induced liver fibrosis.","date":"2023","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/37647804","citation_count":10,"is_preprint":false},{"pmid":"39261902","id":"PMC_39261902","title":"LONP1 alleviates ageing-related renal fibrosis by maintaining mitochondrial homeostasis.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39261902","citation_count":10,"is_preprint":false},{"pmid":"29408517","id":"PMC_29408517","title":"Clinical features of LONP1-related infantile cataract.","date":"2018","source":"Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus","url":"https://pubmed.ncbi.nlm.nih.gov/29408517","citation_count":10,"is_preprint":false},{"pmid":"40332105","id":"PMC_40332105","title":"LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension.","date":"2025","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/40332105","citation_count":8,"is_preprint":false},{"pmid":"36508908","id":"PMC_36508908","title":"Inhibition of Lonp1 induces mitochondrial remodeling and autophagy suppression in cervical cancer cells.","date":"2022","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/36508908","citation_count":8,"is_preprint":false},{"pmid":"40249453","id":"PMC_40249453","title":"The mitochondrial LONP1 protease: molecular targets and role in pathophysiology.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40249453","citation_count":7,"is_preprint":false},{"pmid":"36497197","id":"PMC_36497197","title":"Differential Expression of Lonp1 Isoforms in Cancer Cells.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36497197","citation_count":7,"is_preprint":false},{"pmid":"38184784","id":"PMC_38184784","title":"LONP1 ameliorates liver injury and improves gluconeogenesis dysfunction in acute-on-chronic liver failure.","date":"2024","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/38184784","citation_count":6,"is_preprint":false},{"pmid":"36685982","id":"PMC_36685982","title":"The first case report of CODAS syndrome in Chinese population caused by two LONP1 pathogenic mutations.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36685982","citation_count":6,"is_preprint":false},{"pmid":"38932681","id":"PMC_38932681","title":"Coordinated DNA polymerization by Polγ and the region of LonP1 regulated proteolysis.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38932681","citation_count":5,"is_preprint":false},{"pmid":"39408926","id":"PMC_39408926","title":"Readdressing the Localization of Apolipoprotein E (APOE) in Mitochondria-Associated Endoplasmic Reticulum (ER) Membranes (MAMs): An Investigation of the Hepatic Protein-Protein Interactions of APOE with the Mitochondrial Proteins Lon Protease (LONP1), Mitochondrial Import Receptor Subunit TOM40 (TOMM40) and Voltage-Dependent Anion-Selective Channel 1 (VDAC1).","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39408926","citation_count":5,"is_preprint":false},{"pmid":"40903791","id":"PMC_40903791","title":"Targeting mitochondrial proteases CLPP and LONP1 via disruption of mitochondrial redox homeostasis induces proteotoxic stress and suppresses tumor progression.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40903791","citation_count":5,"is_preprint":false},{"pmid":"39326975","id":"PMC_39326975","title":"Activation of LONP1 by 84-B10 alleviates aristolochic acid nephropathy via re-establishing mitochondrial and peroxisomal homeostasis.","date":"2024","source":"Chinese journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/39326975","citation_count":5,"is_preprint":false},{"pmid":"36362158","id":"PMC_36362158","title":"Roles of LonP1 in Oral-Maxillofacial Developmental Defects and Tumors: A Novel Insight.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362158","citation_count":4,"is_preprint":false},{"pmid":"38139038","id":"PMC_38139038","title":"Mitochondrial p38 Mitogen-Activated Protein Kinase: Insights into Its Regulation of and Role in LONP1-Deficient Nematodes.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38139038","citation_count":4,"is_preprint":false},{"pmid":"38625722","id":"PMC_38625722","title":"Aging of alveolar type 2 cells induced by Lonp1 deficiency exacerbates pulmonary fibrosis.","date":"2024","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38625722","citation_count":4,"is_preprint":false},{"pmid":"40305312","id":"PMC_40305312","title":"Modulation of Lonp1 Activity by Small Compounds.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40305312","citation_count":3,"is_preprint":false},{"pmid":"37392095","id":"PMC_37392095","title":"Decreased LONP1 expression contributes to DNA damage and meiotic defects in oocytes.","date":"2023","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/37392095","citation_count":3,"is_preprint":false},{"pmid":"40784490","id":"PMC_40784490","title":"Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.","date":"2025","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40784490","citation_count":2,"is_preprint":false},{"pmid":"39462050","id":"PMC_39462050","title":"Association of LONP1 gene with epilepsy and the sub-regional effect.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39462050","citation_count":2,"is_preprint":false},{"pmid":"40719285","id":"PMC_40719285","title":"Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence.","date":"2025","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/40719285","citation_count":2,"is_preprint":false},{"pmid":"41257877","id":"PMC_41257877","title":"Single-cell transcriptomics uncovering a critical AKT-LONP1-STAR axis in ovarian hyperandrogenism of PCOS.","date":"2025","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/41257877","citation_count":2,"is_preprint":false},{"pmid":"40931319","id":"PMC_40931319","title":"LONP1 Variants Are Associated With Clinically Diverse Phenotypes.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40931319","citation_count":2,"is_preprint":false},{"pmid":"40044488","id":"PMC_40044488","title":"Dual regulation of Atf3 and Lonp1 as therapeutic targets in cerebral ischaemia-reperfusion injury.","date":"2025","source":"Stroke and vascular neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40044488","citation_count":2,"is_preprint":false},{"pmid":"40691303","id":"PMC_40691303","title":"LONP1 loss causes mitochondrial mayhem in β-cells.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40691303","citation_count":2,"is_preprint":false},{"pmid":"38895283","id":"PMC_38895283","title":"LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38895283","citation_count":1,"is_preprint":false},{"pmid":"41258406","id":"PMC_41258406","title":"Identifying a novel Mecp2-mediated epigenetic mechanism controlling Lonp1 in the hippocampus and its disruption by aging.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41258406","citation_count":1,"is_preprint":false},{"pmid":"40197059","id":"PMC_40197059","title":"Peste des petits ruminants virus (PPRV) induces ferroptosis via LONP1-mediated mitochondrial GPX4 degradation in cell culture.","date":"2025","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40197059","citation_count":1,"is_preprint":false},{"pmid":"40867604","id":"PMC_40867604","title":"Systemic Lonp1 Haploinsufficiency Mitigates Cardiac Mitochondrial Dysfunction Induced by Cardiomyocyte-Specific Lonp1 Haploinsufficiency via Potential Inter-Organ Crosstalk.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40867604","citation_count":1,"is_preprint":false},{"pmid":"40917061","id":"PMC_40917061","title":"LONP1 Promotes Hepatocarcinogenesis by Degrading ACO2 to Alleviate Ferroptosis.","date":"2025","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/40917061","citation_count":0,"is_preprint":false},{"pmid":"41317762","id":"PMC_41317762","title":"N6-methyladenosine (m6A) modification regulates LONP1 to inhibit coxsackievirus B3 replication by suppressing virus-induced ferroptosis.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41317762","citation_count":0,"is_preprint":false},{"pmid":"41620670","id":"PMC_41620670","title":"Role of LONP1 in human diseases: molecular mechanisms and therapeutic potential.","date":"2026","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/41620670","citation_count":0,"is_preprint":false},{"pmid":"41289019","id":"PMC_41289019","title":"Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41289019","citation_count":0,"is_preprint":false},{"pmid":"42219609","id":"PMC_42219609","title":"The Multiple Roles and Targeting Strategies of LonP1 in the Occurrence and Development of Cancer.","date":"2026","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/42219609","citation_count":0,"is_preprint":false},{"pmid":"40157290","id":"PMC_40157290","title":"Sulforaphane downregulates mitochondrial TIGAR via inhibiting mitochondrial transmembrane assembly and LONP1/CASP3 axis causing apoptosis.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/40157290","citation_count":0,"is_preprint":false},{"pmid":"40950177","id":"PMC_40950177","title":"Cryo-EM Reveals Regulatory Mechanisms Governing Substrate Selection and Activation of Human LONP1.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40950177","citation_count":0,"is_preprint":false},{"pmid":"41455337","id":"PMC_41455337","title":"Hypoxia-induced LONP1 overexpression and mtDNA damage may serve as biomarkers for death from mechanical asphyxia.","date":"2025","source":"Legal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/41455337","citation_count":0,"is_preprint":false},{"pmid":"41903616","id":"PMC_41903616","title":"Lonp1 inhibition disrupts mitochondrial function in the hippocampus and drives an aging-like synaptic and cognitive phenotype in adult SAMP8 mice.","date":"2026","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41903616","citation_count":0,"is_preprint":false},{"pmid":"42097003","id":"PMC_42097003","title":"Rare ginsenoside Rk1 protects against cisplatin-induced auditory damage by regulating the MST1/LONP1 pathway.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42097003","citation_count":0,"is_preprint":false},{"pmid":"41900996","id":"PMC_41900996","title":"Structural Analysis of Human LonP1 Protease Bound with the Native Substrate.","date":"2026","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41900996","citation_count":0,"is_preprint":false},{"pmid":"41648325","id":"PMC_41648325","title":"LONP-1 deficiency causes dysregulated protein synthesis within mitochondria that is restored by mitoribosomal mutations.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41648325","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51377,"output_tokens":9608,"usd":0.149125,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20109,"output_tokens":5775,"usd":0.12246,"stage2_stop_reason":"end_turn"},"total_usd":0.271585,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"LONP1 cryo-EM structures reveal that human LONP1 adopts both open and closed spiral staircase orientations dictated by substrate and nucleotide; unlike bacterial Lon, it contains a second spiral staircase within the ATPase domain that engages substrate during translocation. Critically, substrate binding within the central ATPase channel alone is insufficient to induce the activated protease conformation—substrate binding within the protease active site is also required, demonstrating that LONP1 can decouple ATPase and protease activities.\",\n      \"method\": \"Cryo-electron microscopy structural determination; peptidomimetic active-site inhibitor bortezomib used to trap active conformation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures with functional validation via inhibitor trapping in a single rigorous study, multiple conformational states resolved\",\n      \"pmids\": [\"34050165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LONP1 works with the mtHSP70 chaperone system (specifically co-chaperone DNAJA3) to promote mitochondrial protein folding. LONP1 is required for DNAJA3 and mtHSP70 solubility; its ATPase activity (but not protease activity) is required for this chaperone function. In vitro, LONP1 shows intrinsic chaperone-like activity and collaborates with mtHSP70 to stabilize a folding intermediate of OXA1L.\",\n      \"method\": \"siRNA knockdown, in vitro chaperone reconstitution assay, ATPase-dead and protease-dead mutants, mass spectrometry of aggregated proteins\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis (ATPase-dead vs protease-dead) plus cellular knockdown with multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"33431889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LONP1 pathogenic mutations causing CODAS syndrome cluster within the AAA+ domain near the ATP-binding pocket; biochemical assays show substrate-specific defects in ATP-dependent proteolysis, and one Amish variant (p.Arg721Gly) homo-oligomerizes poorly in vitro. Patient lymphoblastoid cells show swollen mitochondria with electron-dense inclusions, aggregated MT-CO2 (mtDNA-encoded COX subunit II), and reduced spare respiratory capacity.\",\n      \"method\": \"Biochemical proteolysis assays with recombinant mutant proteins; native gel oligomerization assay; electron microscopy of patient lymphoblastoid cell mitochondria; immunoblotting\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro enzymatic assays of purified mutant proteins plus cellular characterization, replicated with multiple alleles across two independent studies (PMID 25574826 and 25808063)\",\n      \"pmids\": [\"25574826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LONP1 mediates heme-induced proteolysis of mature ALAS-1 (5-aminolevulinic acid synthase) in the mitochondrial matrix. Inhibition of LONP1 with inhibitors or siRNA knockdown blocks heme- and metalloporphyrin-induced degradation of ALAS-1 protein, establishing LONP1 as the protease responsible for this feedback regulatory step in heme biosynthesis.\",\n      \"method\": \"siRNA knockdown of LONP1; pharmacological inhibition; pulse-chase protein turnover assays in human liver cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two orthogonal loss-of-function approaches (siRNA + inhibitor) with specific substrate readout, replicated across multiple metalloporphyrins\",\n      \"pmids\": [\"21659532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Artemisinins directly target LONP1, enhance the LONP1–CYP11A1 protein interaction, and facilitate LONP1-catalyzed degradation of CYP11A1, thereby suppressing ovarian androgen synthesis. Overexpression of LONP1 alone replicates the androgen-lowering effect.\",\n      \"method\": \"Biochemical binding assays, Co-IP, LONP1 overexpression in rodent PCOS models and human patients, mass spectrometry\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct target engagement demonstrated biochemically, validated in both rodent models and human patients with multiple orthogonal approaches\",\n      \"pmids\": [\"38870290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LONP1 and the mitochondrial processing peptidase MPPαβ are together required for maturation of a subset of mitochondrial matrix proteins (SSBP1, MTERFD3, FASTKD2, CLPX); these proteins accumulate in unprocessed, insoluble form when LONP1 is absent. Prolonged LONP1 depletion also causes loss of mtDNA and suppression of mitochondrial translation via impaired ribosome biogenesis, activates the integrated stress response (ISR), and stabilizes PINK1.\",\n      \"method\": \"Catalytically dead LONP1 mutant expression; MPP depletion; quantitative proteomics; siRNA knockdown; immunoblotting\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic-dead mutant trapping of substrates plus MPP epistasis; multiple orthogonal methods identifying substrate set\",\n      \"pmids\": [\"30061372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mitochondrial LonP1 is phosphorylated by Akt at Ser173 and Ser181, which enhances its protease activity. Interference with this Akt–LonP1 pathway causes accumulation of misfolded subunits of ETC complex II and complex V, impairs oxidative bioenergetics, increases ROS, suppresses mitochondrial trafficking to the cortical cytoskeleton, and inhibits tumor cell migration and invasion.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis of phosphorylation sites, co-immunoprecipitation, mitochondrial trafficking imaging, tumor growth assays in vivo\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro phosphorylation assay with mutagenesis validation plus multiple functional readouts in vitro and in vivo\",\n      \"pmids\": [\"31406245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Purified LonP1-P761L (LONP1 pathogenic variant causing neurodegeneration) fails to degrade phosphorylated PDH E1α subunit in vitro, while wild-type LonP1 degrades it. Overexpressing wild-type LonP1 in patient fibroblasts down-regulates phospho-E1α and rescues PDH activity, demonstrating that LONP1 degrades phospho-E1α to maintain pyruvate dehydrogenase function.\",\n      \"method\": \"In vitro proteolysis assay with purified recombinant proteins; LonP1 overexpression in patient fibroblasts; PDH activity and lactate/pyruvate ratio measurements\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro reconstitution with purified mutant vs wild-type protein; functionally validated in patient fibroblasts\",\n      \"pmids\": [\"30304514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LonP1 mutant p.Tyr565His cannot bind or degrade a substrate in vitro, consistent with the predicted role of this residue. Mixing p.Tyr565His with wild-type LonP1 retains partial protease activity, but mixing p.Tyr565His with p.Glu733Lys severely depletes activity, consistent with compound heterozygosity causing classical mitochondrial disease.\",\n      \"method\": \"In vitro proteolysis assay with purified recombinant single and mixed mutant LonP1 proteins\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro proteolysis with defined single mutants and mixtures; direct mechanistic conclusion about compound heterozygosity\",\n      \"pmids\": [\"29518248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Oxidative post-translational modifications (decreased reduced cysteine, increased tyrosine nitration and protein carbonylation) of LONP1 attenuate its ATP-dependent proteolytic activity in failing mouse hearts. Mitochondria-targeted antioxidants (mitoTEMPO, mitochondria-targeted human catalase) reversed these oxidative modifications and restored LONP1 proteolytic activity; siRNA repression of LONP1 partially canceled the protective antioxidant effects, confirming LONP1 mediates redox-dependent ETC protein turnover.\",\n      \"method\": \"FITC-casein proteolytic activity assay; immunoblotting for oxidative modifications; in vivo siRNA knockdown; mitochondria-targeted antioxidant treatment; cardiac function measurement\",\n      \"journal\": \"Circulation. Heart failure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (activity assay, modification analysis, genetic knockdown, antioxidant rescue) in vivo and in vitro\",\n      \"pmids\": [\"24740269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In C. elegans, LONP-1 (the LONP1 ortholog) degrades ATFS-1 in healthy mitochondria, preventing its accumulation. In dysfunctional mitochondria, LONP-1-mediated ATFS-1 degradation is impaired, allowing ATFS-1 to accumulate and bind the replicative polymerase POLG to ∆mtDNA. LONP-1 inhibition in C. elegans and human cybrid cells increased ATFS-1/POLG binding to wild-type mtDNAs, improving heteroplasmy ratios and restoring oxidative phosphorylation.\",\n      \"method\": \"Genetic loss-of-function (lonp-1 deletion), ChIP for POLG-mtDNA binding, heteroplasmy quantification, LONP-1 inhibitor treatment in C. elegans and human cybrids, respirometry\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis plus ChIP plus pharmacological intervention replicated across two organisms (C. elegans and human cybrids)\",\n      \"pmids\": [\"35165413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Skeletal muscle-specific ablation of LONP1 in mice causes impaired mitochondrial protein turnover leading to mitochondrial dysfunction, reduced muscle fiber size and strength. Mechanistically, accumulation of mitochondrial-retained protein activates the autophagy-lysosome degradation program. Overexpression of ΔOTC (a known LONP1 substrate) in skeletal muscle recapitulates mitochondrial dysfunction, autophagy activation, muscle loss, and weakness.\",\n      \"method\": \"Conditional muscle-specific LONP1 knockout mice; ΔOTC overexpression; respirometry; autophagy markers; muscle fiber histology and strength testing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular phenotype plus substrate overexpression epistasis experiment confirming mechanism\",\n      \"pmids\": [\"35173176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LONP1 selectively degrades succinate dehydrogenase complex iron sulfur subunit B (SDHB) in mature white adipocytes during thermogenic stimulation. LONP1-mediated SDHB degradation raises intracellular succinate levels, altering histone methylation status on thermogenic genes and enabling white-to-beige adipocyte cell fate programming. Disruption of LONP1-dependent proteolysis impairs cold- or β3 adrenergic agonist-induced beige conversion.\",\n      \"method\": \"Conditional LONP1 disruption in mature adipocytes; mass spectrometry substrate identification; succinate metabolomics; histone methylation ChIP; cold/β3-agonist treatment in vivo and in vitro\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate identified by proteomics and validated functionally; metabolomics and histone ChIP provide mechanistic link; multiple orthogonal methods in one study\",\n      \"pmids\": [\"37217599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LONP1 degrades HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) in the mitochondrial matrix; LONP1 downregulation causes aberrant HMGCS2 accumulation that disrupts mitochondrial function and accelerates chronic kidney disease progression.\",\n      \"method\": \"Tubular-specific Lonp1 overexpression and deletion in CKD mouse models; in vitro proteolysis validation; mass spectrometry substrate identification; renal function and mitochondrial function assays\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain- and loss-of-function in vivo with substrate identification by proteomics and in vitro validation\",\n      \"pmids\": [\"36629048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LonP1 overexpression in mouse hearts protects against ischemia/reperfusion injury by reducing oxidative protein damage, maintaining mitochondrial redox homeostasis, and downregulating Complex I protein levels and activity. LonP1 haploinsufficiency abrogates ischemic preconditioning-mediated cardioprotection and increases infarct size. In NRVMs, LonP1 knockdown upregulates Complex I subunits and ETC activities, increases superoxide production, and causes mitochondrial inner membrane dysmorphology and hyperpolarization.\",\n      \"method\": \"Cardiac-specific LonP1 transgenic overexpression mice; LonP1+/− haploinsufficient mice; siRNA knockdown in NRVMs; in vivo I/R injury model; respirometry; ETC activity assays\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — both gain- and loss-of-function genetic models with multiple mechanistic readouts in vivo and in vitro\",\n      \"pmids\": [\"30625302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LONP1 directly interacts with AIFM1 (apoptosis-inducing factor, mitochondria-associated 1); LONP1 ablation in mouse oocytes causes translocation of AIFM1 from cytoplasm to nucleus, triggering apoptosis and progressive oocyte death. Conditional knockout of Lonp1 in oocytes impairs follicular development and causes infertility.\",\n      \"method\": \"Conditional oocyte-specific Lonp1 knockout mice; Co-IP/LC-MS; immunofluorescence for AIFM1 localization; follicle counting; fertility assays\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular phenotype; AIFM1 interaction confirmed by Co-IP/MS with localization tracking\",\n      \"pmids\": [\"34974310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LONP1 is identified as a novel mitochondria-associated membrane (MAM) tethering protein; removal of LonP1 substantially reduces MAM formation and causes mitochondrial fragmentation. Cardiac-specific LonP1 deletion impairs MAM integrity, mitochondrial fusion, and activates ER unfolded protein response (UPRER), causing metabolic reprogramming and pathological heart remodeling.\",\n      \"method\": \"Conditional cardiac-specific LonP1 knockout mice; MAM fractionation; mitochondrial morphology imaging; ER stress markers; cardiac phenotyping\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with MAM fractionation and multiple phenotypic readouts in single lab\",\n      \"pmids\": [\"37333972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CDDO and its methyl and imidazole derivatives reversibly inhibit LonP1 by a noncompetitive mechanism, blocking ATP hydrolysis and thus proteolysis (allosteric inhibition). CDDO-anhydride inhibits LonP1 ATPase competitively. Docking of CDDO derivatives in the cryo-EM structure identifies a hydrophobic pocket adjacent to the ATP-binding site. A CODAS-causing pathogenic mutation ablates CDDO inhibition. CDDO fails to inhibit the 26S proteasome ATPase, showing selectivity within the AAA+ family.\",\n      \"method\": \"In vitro ATPase and protease activity assays; competitive vs. noncompetitive kinetic analysis; cryo-EM structure-based docking; site-directed mutagenesis validation; cell-based inhibition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinetic mechanism determination with mutagenesis and structural docking; specificity validated against 26S proteasome; multiple orthogonal methods\",\n      \"pmids\": [\"35151690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Sirt3 deacetylates LONP1 at lysine 145 (K145) in the N-terminal domain; deacetylation subsequently facilitates ESCRT0 complex sorting and K63-linked ubiquitination of LONP1, resulting in its degradation. Hyperacetylation-mimetic LONP1-K145Q enhances oxidative phosphorylation and accelerates tumor growth, while deacetylation-mimetic K145R produces a calorie-restriction-like phenotype restraining tumorigenesis.\",\n      \"method\": \"Mass spectrometry identification of deacetylation site; K145Q/K145R mutagenesis; Sirt3 conditional intestinal knockout mice; Seahorse metabolic analysis; ubiquitination assays\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — MS identification of modification site with mutagenesis validation; in vivo conditional KO; functional metabolic readouts; multiple orthogonal methods\",\n      \"pmids\": [\"36739437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"De novo LONP1 mutation p.R301W (located in the N-terminal domain) causes a mitochondrial encephalopathy phenotype characterized by excessive LONP1 proteolytic activity (degrading known substrates TFAM, PINK1, phospho-PDH E1α, mitoribosome subunits MRPL44/MRPL11) combined with loss of LONP1 chaperone activity. The N-terminal domain is required for hexamer stability and for conformational changes necessary to balance proteolytic and chaperone activities.\",\n      \"method\": \"Functional studies in patient fibroblasts; immunoblotting for proteolytic substrates; respiratory chain activity assays; hexamer stability assays with N-terminal domain mutations\",\n      \"journal\": \"Mitochondrion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular functional studies with multiple substrate readouts in single lab; hexamer stability assay; mechanistic conclusion about N-terminal domain\",\n      \"pmids\": [\"31923470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NEK5 kinase interacts with LonP1 within mitochondria and may be involved in the LonP1-TFAM signaling module. NEK5 kinase activity is required for maintaining mitochondrial mass, functionality, and mtDNA integrity after oxidative damage.\",\n      \"method\": \"Co-immunoprecipitation of NEK5 and LonP1; NEK5 kinase-dead mutants; mitochondrial mass and mtDNA integrity assays after oxidative damage\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP interaction confirmed; kinase-dead mutagenesis establishes kinase requirement; mitochondrial phenotype readout; single lab\",\n      \"pmids\": [\"33547867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LONP1 and ClpP share substrates including SHMT2; depletion of both proteases synergistically increases accumulation of unfolded SHMT2, confirming functional substrate overlap. APEX-mediated proximity proteomics identified the specific substrate sets of LONP1 and ClpP within the mitochondrial matrix, including components of OXPHOS, TCA cycle, amino acid and lipid metabolism.\",\n      \"method\": \"APEX-mediated proximity biotinylation/proteomics; siRNA depletion of LONP1 and ClpP individually and combined; immunoblotting for SHMT2 folding status; cell growth and death assays\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — APEX proximity proteomics with genetic depletion; shared substrate validated by unfolded protein accumulation; single lab\",\n      \"pmids\": [\"33637676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mitochondrial LonP1 protease is implicated in the degradation of unstable Parkinson's disease-associated DJ-1/PARK7 missense mutants (A107P, P158Δ, L166P, E163K, L172Q) that associate with mitochondria. siRNA silencing of LONP1 strongly reduces degradation of these mitochondria-associated DJ-1 mutants.\",\n      \"method\": \"siRNA knockdown of LONP1; immunofluorescence and biochemical fractionation to assess DJ-1 mutant localization; pulse-chase degradation assays in DJ-1-null MEFs\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with direct substrate degradation readout; fractionation confirms mitochondrial localization; single lab\",\n      \"pmids\": [\"33795807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LONP1 depletion in mouse oocytes during myoblast differentiation causes mitochondrial depolarization, suppresses the PINK1/Parkin pathway, and reduces Mfn2 and Drp1 levels, blocking mitochondrial remodeling and myoblast differentiation into myotubes. LonP1 promotes myoblast differentiation by regulating PINK1/Parkin-mediated mitochondrial network remodeling.\",\n      \"method\": \"siRNA knockdown of LonP1 in C2C12 myoblasts; PINK1/Parkin pathway immunoblotting; mitochondrial membrane potential assay; fusion/fission protein levels; differentiation assays\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined cellular differentiation phenotype and pathway marker readouts; single lab\",\n      \"pmids\": [\"32936696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LONP1 is detected in the nucleus (up to 22% of total cellular LONP1). Nuclear LONP1 interacts with heat shock factor 1 (HSF1) and modulates the heat shock response. Nuclear localization is detectable under all conditions but increases in response to heat shock.\",\n      \"method\": \"Subcellular fractionation; immunofluorescence; Co-immunoprecipitation of LONP1 with HSF1; quantification of nuclear fraction under heat shock\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — fractionation plus Co-IP with HSF1; nuclear localization confirmed but functional link to HSF1 regulation is Co-IP-level evidence; single lab\",\n      \"pmids\": [\"35760833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of human LonP1 engaging its native substrate TFAM reveals a bipartite search-and-shred mechanism: the N-terminal domain acts as a selective vestibule to recruit and initially unfold substrate tertiary structure, then polypeptide is threaded through the central channel via a hand-over-hand mechanism driven by aromatic pore-loops. Chemical crosslinking mass spectrometry and site-directed mutagenesis uncovered the region of LonP1 engagement of PolG (the catalytic subunit of the mitochondrial replicative polymerase), which promotes proteolysis and regulation of PolG protein levels; PolG2 clinical variants that disrupt a stable Polγ complex lead to enhanced LonP1-mediated PolG degradation.\",\n      \"method\": \"Single-particle cryo-EM structure of LonP1–TFAM complex; chemical crosslinking mass spectrometry; site-directed mutagenesis; in vitro proteolysis assay of PolG\",\n      \"journal\": \"Nucleic acids research / Life (Basel)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with crosslinking MS and mutagenesis in two independent complementary studies\",\n      \"pmids\": [\"38932681\", \"41900996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A novel ADP-bound, C3-symmetric intermediate state of LONP1 (LONP1C3) is resolved by cryo-EM. This intermediate is stabilized by interaction with folded substrates and is proposed to have 'fold-sensing' capabilities. Additional symmetric and asymmetric states, including a two-fold symmetric split-hexamer conformation, are associated with the transition from LONP1C3 to the active enzyme (LONP1ENZ), providing mechanistic insight into how substrate selection and engagement regulate unfoldase activation.\",\n      \"method\": \"Cryo-electron microscopy; biochemical ATPase and protease assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — high-resolution structural work but preprint, single study not yet peer-reviewed\",\n      \"pmids\": [\"40950177\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FBXO11 interacts with LONP1 in the cytosol and catalyzes K63-linked ubiquitination of LONP1 to promote its entry into mitochondria. FBXO11 or LONP1 depletion reduces mitochondrial respiration through impaired LONP1 chaperone activity for assembling ETC Complex IV. This reduced mitochondrial respiration imparts myeloid-biased stem cell properties in CD34+ HSPCs.\",\n      \"method\": \"Co-IP of FBXO11 and LONP1; ubiquitination assay specifying K63-linkage; shRNA depletion; respirometry; Complex IV assembly assay; human xenograft model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus K63-ubiquitination assay plus functional mitochondrial and cellular rescue experiments across in vitro and in vivo xenograft models\",\n      \"pmids\": [\"41289019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LONP1 degrades DHODH (dihydroorotate dehydrogenase) in hepatocytes in an ATP-dependent manner, thereby lowering orotic acid levels and suppressing ATF3-mediated activation of hepatic stellate cells. Hepatocyte-specific LONP1 deficiency causes DHODH accumulation, elevated orotic acid, and aggravated MASH-induced liver fibrosis; LONP1 overexpression or DHODH inhibition reverses this.\",\n      \"method\": \"Hepatocyte-specific Lonp1 knockout mice; LONP1 overexpression; transcriptomics/proteomics/metabolomics; in vitro ATP-dependent proteolysis of DHODH; liver biopsy correlation in human MASH patients\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro ATP-dependent proteolysis assay; conditional KO and overexpression in vivo; metabolomics substrate validation; human patient correlation\",\n      \"pmids\": [\"40784490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LONP1 degrades MPC1 (mitochondrial pyruvate carrier 1) directly; LONP1-mediated MPC1 degradation promotes glycolytic reprogramming and proliferation/migration of pulmonary artery smooth muscle cells in pulmonary hypertension. Rescue experiments confirm MPC1 knockdown abrogates suppressive effects of LONP1 knockdown on glycolysis and proliferation.\",\n      \"method\": \"LONP1 knockdown and overexpression in PASMCs; MPC1 knockdown and overexpression rescue experiments; in vivo LONP1 knockdown in rat PH models; glycolysis and proliferation assays\",\n      \"journal\": \"Clinical science (London, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate-rescue epistasis experiment confirms mechanism; in vivo validation; single lab, direct proteolysis not reconstituted in vitro\",\n      \"pmids\": [\"40332105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cardiac-specific deletion of Lonp1 in mouse embryos causes severely impaired heart development and embryonic lethality, with mitochondrial swelling, cristae loss, and abnormal protein aggregates. Mechanistically, loss of LONP1 triggers the p-eIF2α–ATF4 pathway; nuclear ATF4 negatively regulates Tfam and promotes Glut1, disrupting the metabolic shift from glycolysis to oxidative phosphorylation required for heart development.\",\n      \"method\": \"Cardiac-specific conditional Lonp1 knockout mice (embryonic); electron microscopy; ATF4 nuclear translocation assay; Tfam and Glut1 gene expression analysis; metabolic function assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined embryonic lethal phenotype; downstream pathway mechanism (ATF4-Tfam-Glut1) established by gene expression and nuclear translocation\",\n      \"pmids\": [\"35237793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LONP1 promotes β-cell survival and prevents hyperglycemia by facilitating mitochondrial protein folding via its chaperone activity in cooperation with mtHSP70. LONP1 deletion causes mitochondrial protein misfolding, reduced respiratory function, β-cell apoptosis, and hyperglycemia. LONP1 gain-of-function restores human β-cell survival after glucolipotoxicity via a protease-independent mechanism requiring LONP1–mtHSP70 chaperone activity.\",\n      \"method\": \"Conditional LONP1 knockout mice; LONP1 overexpression in human islets; quantitative proteomics of protein aggregates; respirometry; β-cell apoptosis assays; protease-dead vs. chaperone mutants\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO and gain-of-function with protease-dead vs. chaperone mutant distinction; quantitative proteomics; human islet validation; multiple orthogonal approaches\",\n      \"pmids\": [\"40691304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LONP1 degrades ACO2 (aconitase 2) to promote hepatocellular carcinoma cell proliferation, migration, and reduced susceptibility to ferroptosis and cuproptosis. LONP1 overexpression leads to decreased mitochondrial membrane potential (mitochondrial dysfunction) and reduced ACO2 protein, inhibiting ferroptosis.\",\n      \"method\": \"LONP1 overexpression and knockdown in HCC cell lines; subcutaneous tumor xenografts; histological co-staining of LONP1 and ACO2; mitochondrial membrane potential assay; ferroptosis/cuproptosis assays\",\n      \"journal\": \"Frontiers in bioscience (Landmark edition)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — substrate relationship between LONP1 and ACO2 inferred from co-staining and OE/KD without direct in vitro proteolysis reconstitution; single lab\",\n      \"pmids\": [\"40917061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LONP-1 (C. elegans LONP1 ortholog) deficiency causes dysregulation of mitochondrial DNA replication, mitochondrial RNA transcription, and protein synthesis. Suppressor mutations in genes encoding mitochondrial ribosome proteins (MRPS-38, MRPS-15) restore mitochondrial function and oxidative phosphorylation in lonp-1 mutants, suggesting LONP-1 regulates mitochondrial protein synthesis and that slowing translation corrects OXPHOS complex assembly defects.\",\n      \"method\": \"Forward genetic suppressor screen in C. elegans; lonp-1 deletion mutants; mitoribosome gene mutagenesis; respirometry; mtDNA replication and transcription assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (suppressor screen) with defined functional rescue; preprint status reduces confidence\",\n      \"pmids\": [\"41648325\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"LONP1 is an ATP-dependent AAA+ serine protease of the mitochondrial matrix that functions as both a selective protease—degrading oxidized, misfolded, and regulated substrates (including ALAS-1, CYP11A1, TFAM, phospho-PDH E1α, SDHB, HMGCS2, DHODH, MPC1, ACO2, DJ-1 mutants, and PolG)—and an ATP-dependent molecular chaperone that collaborates with the mtHSP70/DNAJA3 system to facilitate protein folding; its proteolytic activity is regulated by Akt-mediated phosphorylation (at Ser173/181), Sirt3-mediated deacetylation (at K145) coupled to K63-ubiquitination and degradation, FBXO11-mediated K63-ubiquitination required for mitochondrial import, and reversible oxidative post-translational modifications; structurally, LONP1 adopts open/closed spiral staircase hexameric conformations gated by both ATPase- and protease-domain substrate engagement, with a C3-symmetric intermediate proposed to sense folded substrates before activating the unfoldase; beyond the matrix it is also found at mitochondria-ER contact sites (MAMs) and in the nucleus where it interacts with HSF1 to modulate the heat shock response.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LONP1 is an ATP-dependent AAA+ serine protease of the mitochondrial matrix that governs mitochondrial proteostasis by selectively degrading regulatory, misfolded, and oxidatively damaged proteins while doubling as an ATP-dependent chaperone [#1, #5, #25]. Its enzyme cycle is built on a bipartite \\\"search-and-shred\\\" architecture: the N-terminal domain acts as a selective vestibule that recruits and initially unfolds substrate, after which polypeptide is threaded through a central channel by aromatic pore-loops in a hand-over-hand mechanism, with a second ATPase-domain spiral staircase engaging substrate during translocation [#0, #25]. Critically, ATPase and protease activities are decoupled—substrate occupancy of both the central channel and the protease active site is required to license the activated conformation—and an ADP-bound C3-symmetric intermediate is positioned to sense folded substrate before unfoldase activation [#0, #26]. Through this proteolysis LONP1 sets the levels of a broad regulated substrate set spanning heme synthesis (ALAS-1), steroidogenesis (CYP11A1), mtDNA maintenance and transcription (TFAM, PolG), central carbon and one-carbon metabolism (phospho-PDH E1α, SDHB, ACO2, MPC1, SHMT2), ketogenesis and pyrimidine metabolism (HMGCS2, DHODH), and disease-associated misfolded proteins (DJ-1 mutants) [#3, #4, #7, #12, #13, #21, #25, #28, #29]. Independently of proteolysis, its ATPase-driven chaperone activity cooperates with the mtHSP70/DNAJA3 system to fold matrix proteins and assemble respiratory complexes [#1, #31]. LONP1 activity is tuned by Akt phosphorylation at Ser173/181, reversible oxidative modifications, Sirt3 deacetylation at K145, and FBXO11-mediated K63-ubiquitination that drives its mitochondrial import [#6, #9, #18, #27]. Loss-of-function and gain-of-function studies link LONP1 to muscle, cardiac, β-cell, hepatic, and oocyte homeostasis, and to integrated stress and unfolded-protein responses [#11, #14, #15, #30, #31]. Pathogenic LONP1 mutations clustering in the AAA+ and N-terminal domains cause CODAS syndrome and mitochondrial encephalopathy/neurodegeneration through substrate-specific proteolytic defects and imbalance of protease versus chaperone function [#2, #7, #8, #19]. Beyond the matrix, LONP1 is detected at mitochondria-ER contact sites as a MAM tethering factor and in the nucleus, where it interacts with HSF1 [#16, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that LONP1 is not merely a bulk quality-control protease but a regulated effector of a metabolic pathway, by identifying its role in feedback control of heme biosynthesis.\",\n      \"evidence\": \"siRNA and pharmacological inhibition with pulse-chase turnover of ALAS-1 in human liver cells\",\n      \"pmids\": [\"21659532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct in vitro proteolysis of ALAS-1 not reconstituted\", \"Mechanism of heme-induced substrate recognition unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that LONP1 proteolytic activity is itself redox-regulated, linking oxidative damage to its own functional decline in disease.\",\n      \"evidence\": \"FITC-casein activity assays, oxidative modification immunoblotting, in vivo siRNA, and mitochondria-targeted antioxidant rescue in failing mouse hearts\",\n      \"pmids\": [\"24740269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific oxidized residues controlling activity not mapped\", \"Which ETC substrates accumulate not fully defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected LONP1 to human Mendelian disease, defining CODAS syndrome and demonstrating that AAA+-domain mutations cause substrate-specific proteolytic and oligomerization defects.\",\n      \"evidence\": \"Recombinant mutant proteolysis assays, native-gel oligomerization, and electron microscopy of patient lymphoblastoid mitochondria\",\n      \"pmids\": [\"25574826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue specificity of clinical phenotype unexplained\", \"Full substrate spectrum disrupted by mutations unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a broad LONP1-dependent maturation and turnover network and showed its depletion triggers integrated stress, PINK1 stabilization, and loss of mtDNA/translation, framing LONP1 as central to matrix proteostasis.\",\n      \"evidence\": \"Catalytic-dead mutant substrate trapping, MPP epistasis, quantitative proteomics, and siRNA\",\n      \"pmids\": [\"30061372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect substrate processing not always distinguished\", \"Mechanism linking depletion to ribosome biogenesis loss unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided biochemical mechanism for compound heterozygous mitochondrial disease by showing differential proteolytic complementation between mutant LonP1 subunits within hexamers.\",\n      \"evidence\": \"In vitro proteolysis of purified single and mixed mutant LonP1 proteins\",\n      \"pmids\": [\"29518248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hexamer subunit stoichiometry in patients not measured\", \"Cellular consequences not directly assayed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified post-translational control of LONP1 by Akt phosphorylation and a specific substrate (phospho-PDH E1α), linking LONP1 activity to bioenergetics, redox, and tumor cell motility.\",\n      \"evidence\": \"In vitro kinase assays with phospho-site mutagenesis, patient-fibroblast rescue, and tumor and trafficking readouts\",\n      \"pmids\": [\"31406245\", \"30304514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation alters hexamer conformation not structurally resolved\", \"Phosphatase reversing the modification unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated dose-dependent cardioprotective and ETC-regulatory roles of LONP1 in ischemia/reperfusion using both gain- and loss-of-function models.\",\n      \"evidence\": \"Cardiac transgenic overexpression and haploinsufficient mice, NRVM knockdown, in vivo I/R, and respirometry\",\n      \"pmids\": [\"30625302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates mediating Complex I downregulation not all identified\", \"Relationship to preconditioning signaling incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked LONP1 to differentiation and to a gain-of-function neurodegeneration mechanism, showing that imbalance toward excess proteolysis at the expense of chaperone function is itself pathogenic.\",\n      \"evidence\": \"Patient-fibroblast substrate immunoblotting and hexamer stability assays for p.R301W; C2C12 siRNA and PINK1/Parkin pathway analysis\",\n      \"pmids\": [\"31923470\", \"32936696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"N-terminal domain conformational control inferred indirectly\", \"Single-lab functional characterization without structural confirmation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the structural basis of LONP1 catalysis, showing dual spiral staircases and the requirement of both ATPase-channel and protease-site substrate engagement to activate proteolysis, explaining ATPase/protease decoupling.\",\n      \"evidence\": \"Cryo-EM in multiple conformational states with bortezomib active-site trapping\",\n      \"pmids\": [\"34050165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native folded-substrate engagement not captured in this study\", \"How specific substrates select between states unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Separated LONP1 chaperone function from its protease activity, showing ATPase-dependent collaboration with mtHSP70/DNAJA3 to fold matrix proteins.\",\n      \"evidence\": \"siRNA, in vitro chaperone reconstitution with OXA1L, and ATPase-dead versus protease-dead mutants\",\n      \"pmids\": [\"33431889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of chaperone handoff to mtHSP70 unknown\", \"Full chaperone client set undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the substrate landscape and partner network, defining functional overlap with ClpP (shared substrate SHMT2), the NEK5-LonP1-TFAM module, AIFM1 control of oocyte survival, and degradation of mitochondria-associated DJ-1 mutants.\",\n      \"evidence\": \"APEX proximity proteomics with dual protease depletion; Co-IP of NEK5 and AIFM1; oocyte conditional KO; siRNA pulse-chase of DJ-1 mutants\",\n      \"pmids\": [\"33637676\", \"33547867\", \"34974310\", \"33795807\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NEK5 phosphorylation of LonP1 not directly shown\", \"DJ-1 mutant degradation not reconstituted in vitro\", \"Several interactions rest on single Co-IP\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended LONP1 beyond matrix proteolysis to ATFS-1/UPRmt-coupled mtDNA quality control, MAM tethering, and ER-stress/development signaling, and tied substrate accumulation to autophagy and muscle wasting.\",\n      \"evidence\": \"C. elegans/cybrid genetics with ChIP and heteroplasmy; muscle and cardiac conditional KO with ΔOTC substrate epistasis; embryonic cardiac KO with ATF4-Tfam-Glut1 analysis; MAM fractionation\",\n      \"pmids\": [\"35165413\", \"35173176\", \"35237793\", \"37333972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MAM tethering mechanism is single-lab/Medium evidence\", \"How matrix protease activity produces ER/MAM phenotypes mechanistically unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined selective small-molecule pharmacology of LonP1 and detected a nuclear LONP1 pool interacting with HSF1, broadening its regulatory reach.\",\n      \"evidence\": \"In vitro ATPase/protease kinetics and cryo-EM docking of CDDO derivatives with mutagenesis; subcellular fractionation and Co-IP of nuclear LONP1 with HSF1\",\n      \"pmids\": [\"35151690\", \"35760833\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of LONP1-HSF1 interaction rests on Co-IP\", \"Nuclear LONP1 import/processing route unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified additional regulated substrates that couple LONP1 to metabolic and epigenetic programming (SDHB-succinate-histone methylation in beiging; HMGCS2 in kidney) and a deacetylation/ubiquitination switch controlling LONP1 stability.\",\n      \"evidence\": \"Adipocyte and renal conditional KO/overexpression with proteomics and metabolomics; MS site mapping of K145, Sirt3 KO, and K63-ubiquitination assays\",\n      \"pmids\": [\"37217599\", \"36629048\", \"36739437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ESCRT0-mediated LONP1 turnover route incompletely defined\", \"Tissue specificity of substrate selection unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Captured LonP1 engaging a native substrate (TFAM) to define the search-and-shred mechanism and mapped PolG engagement, linking LONP1 to mitochondrial polymerase regulation and drug-induced (artemisinin) substrate degradation.\",\n      \"evidence\": \"Cryo-EM of LonP1-TFAM, crosslinking MS and mutagenesis on PolG, in vitro proteolysis; biochemical binding and Co-IP for artemisinin-enhanced CYP11A1 degradation in PCOS models\",\n      \"pmids\": [\"38932681\", \"41900996\", \"38870290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability of N-domain vestibule selectivity to all substrates untested\", \"Artemisinin binding site on LONP1 not structurally resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved a fold-sensing C3-symmetric intermediate and defined import-coupled and metabolic roles, including FBXO11-driven mitochondrial import, chaperone-dependent β-cell survival, and proteolytic control of DHODH, MPC1, and ACO2 across disease contexts.\",\n      \"evidence\": \"Cryo-EM intermediate states (preprint); Co-IP and K63-ubiquitination with respirometry (FBXO11); conditional KO/overexpression with protease-dead vs chaperone mutants and human islet/MASH/PH/HCC models\",\n      \"pmids\": [\"40950177\", \"41289019\", \"40691304\", \"40784490\", \"40332105\", \"40917061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intermediate-state model is preprint and awaits peer review\", \"ACO2 substrate relationship inferred without in vitro reconstitution\", \"How FBXO11 K63-ubiquitination mechanistically promotes import unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LONP1 integrates its multiple post-translational regulatory inputs (phosphorylation, oxidation, acetylation, ubiquitination) with conformational state to select among its diverse substrates, and how nuclear/MAM pools are established and function, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state to substrate choice\", \"Nuclear LONP1 function beyond HSF1 Co-IP undefined\", \"Structural basis of extramitochondrial localization unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 5, 7, 13, 25, 28]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 7, 13, 28]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1, 17, 28]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [1, 31]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 5, 25]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 5, 25, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 7, 12, 13, 28, 29]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [5, 9, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 7, 8, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DNAJA3\", \"HSPA9\", \"CYP11A1\", \"AIFM1\", \"HSF1\", \"NEK5\", \"FBXO11\", \"POLG\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}